Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
Inc. Magazine Announces Its 27th Annual List of America’s 5000 Fastest-Growing Private Companies
Colorado Springs, Colo. August 28, 2008– Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
As an Inc. 5000 honoree, Coast Independent Review is now a member of the most influential business clubs in America. The company you keep is notable, as Inc. 5000 alumni include Bill gates of Microsoft, Larry Ellison of Oracle, and many more. The Inc. 5000 is ranked according to percentage revenue growth from 2004 through 2007.
Coast Independent Review Board (IRB) safeguards the rights and well-being of clinical research trial participants for Phase I-IV pharmaceutical, medical device and repository trials. Coast IRB’s associates focus on the customer. “We continue to look for new ways to keep our customer relationships central to our process,” states Darren McDaniel Founder & Managing Director. Additionally, McDaniel promotes educational opportunities to help improve the standards in the industry. This month Coast IRB sponsored a contest to test the ethical savvy of clinical associates. Coast will continue to renovate progress with in the industry by promoting ethical reforms. As part of its continual quest for improvement, Coast IRB is in the process of achieving accreditation with the Association for the Accreditation of Human Research Protection Program (AAHRPP) which ensures high-quality human research protection programs in order to promote excellent, ethically sound research.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.